{"as_of": "2026-11-01", "source_url": "https://drugnews.com.tw/landscapes/asia-adc.html", "headers": ["排名", "資產", "國際非專利藥名", "原研公司", "國家", "標的", "載荷", "最高階段", "適應症", "試驗編號", "亞洲以外權利持有人", "交易日期", "最新事件", "最新事件日期", "來源", "來源日期"], "rows": [["3", "Padcev (ASG-22ME) [co-originated]", "enfortumab vedotin", "Astellas Pharma (Japan) co-developed with Seagen (US, now Pfizer)", "Japan (co-originated with US company)", "Nectin-4", "MMAE (tubulin inhibitor)", "Approved (FDA first approval Dec 2019)", "Urothelial cancer; newest: perioperative MIBC with pembrolizumab regardless of cisplatin eligibility", "NCT04700124 (EV-304); NCT04223856 (EV-302)", "Co-owned Astellas & Pfizer (Seagen acquired by Pfizer 2023-12-14) - not a license-out", "", "FDA approved Padcev + Keytruda neoadjuvant/adjuvant MIBC regardless of cisplatin eligibility (EV-304)", "2026-07-13", "newsroom.astellas.com www.chemexpress.com", "2026-07-13"], ["2", "Datroway (DS-1062)", "datopotamab deruxtecan", "Daiichi Sankyo", "Japan", "TROP2", "DXd (topoisomerase I inhibitor)", "Approved (FDA first approval Jan 2025)", "Breast cancer, NSCLC; newest: 1L metastatic TNBC not candidates for PD-(L)1", "NCT05374512 (TROPION-Breast02)", "AstraZeneca (Daiichi keeps Japan)", "2020-07", "US approval in 1L TNBC (TROPION-Breast02)", "2026-05-26", "www.lse.co.uk clinicaltrials.gov www.chemexpress.com", "2026-05-26"], ["1", "Enhertu (DS-8201)", "trastuzumab deruxtecan", "Daiichi Sankyo", "Japan", "HER2", "DXd (topoisomerase I inhibitor)", "Approved (FDA first approval Dec 2019; also NMPA etc.)", "HER2+ / HER2-low breast cancer and others; newest: HER2+ early breast cancer (neoadjuvant DB-11, adjuvant DB-05)", "NCT04622319 (DESTINY-Breast05); NCT05113251 (DESTINY-Breast11)", "AstraZeneca (global co-development/commercialisation; Daiichi keeps Japan)", "2019-03", "NMPA approved adjuvant HER2+ early BC (DB-05), 9th China indication; FDA approved DB-05 + DB-11 early-BC indications on 2026-05-15", "2026-09-29", "news.10jqka.com.cn www.astrazeneca.com www.chemexpress.com", "2026-10-09"], ["6", "Aiweida (SHR-A1811)", "trastuzumab rezetecan", "Jiangsu Hengrui Pharmaceuticals", "China", "HER2", "SHR9265 (topoisomerase I inhibitor)", "Approved (NMPA, first approval May 2025; 3 China indications)", "HER2-mutant NSCLC (first); HER2+ breast cancer; HER2+ colorectal cancer (3rd, 2026-08)", "NCT06057610; NCT06123494; SHR-A1811-III-309 (HORIZON CRC01)", "Glenmark (emerging markets only; excludes Greater China, US, Canada, Europe, Japan, Russia/CIS)", "2025-09-24", "NMPA approved 3rd indication HER2+ CRC; HER2-low BC sNDA accepted with priority review 2026-07-08", "2026-08-06", "static.cninfo.com.cn news.10jqka.com.cn www.theweek.in", "2026-08-06"], ["8", "Meiyouheng (MRG003)", "becotatug vedotin", "Lepu Biopharma / Shanghai Miracogen", "China", "EGFR", "MMAE (tubulin inhibitor)", "Approved (NMPA)", "R/M nasopharyngeal carcinoma after >=2 lines chemo and PD-(L)1", "NCT05751512 (Ph3 SCCHN, ongoing); NCT06976190 (Ph3 NPC combo)", "", "", "NMPA approval, first approved EGFR ADC (pivotal Ph2: ORR 30.2% vs 11.5%)", "2025-10-30", "global.pharmcube.com www.chemexpress.com", "2025-11-04"], ["4", "Aidixi (RC48)", "disitamab vedotin", "RemeGen", "China", "HER2", "MMAE (tubulin inhibitor)", "Approved (NMPA, first approval Jun 2021)", "HER2+ gastric cancer (first); newest: 1L HER2-expressing urothelial carcinoma with toripalimab", "NCT05302284 (RC48-C016)", "Seagen, now Pfizer (worldwide ex-RemeGen territory; RemeGen keeps Asia excl. Japan & Singapore)", "2021-08-09", "NMPA approved DV + toripalimab 1L HER2-expressing la/mUC (RC48-C016: PFS 13.1 vs 6.5 mo; OS 31.5 vs 16.9 mo)", "2026-05-22", "news.qq.com www.cancernetwork.com www.businesswire.com", "2026-05-22"], ["9", "Yizekang (BL-B01D1 / BMS-986507)", "izalontamab brengitecan", "Sichuan Baili Pharmaceutical (Biokin) / SystImmune", "China", "EGFR x HER3 (bispecific)", "Ed-04 (topoisomerase I inhibitor)", "Approved (NMPA conditional; first approved bispecific ADC)", "R/M nasopharyngeal carcinoma (2026-06-22); 2L R/M ESCC (2026-07-17)", "NCT06118333 (NPC Ph3); NCT06304974 (ESCC Ph3); NCT07100080 (BMS global Ph3)", "Bristol Myers Squibb (ex-mainland China)", "2023-12 (announced 2023-12-11/12; $800M upfront)", "NMPA approved 2nd indication (ESCC) 25 days after NPC approval", "2026-07-17", "www.biochempeg.com www.biopharminternational.com www.biopharminternational.com", "2026-08-20"], ["5", "Jiatailai (SKB264 / MK-2870)", "sacituzumab tirumotecan", "Sichuan Kelun-Biotech", "China", "TROP2", "KL610023 (topoisomerase I inhibitor)", "Approved (NMPA, first approval Nov 2024; 4 China approvals in breast cancer & NSCLC)", "Breast cancer; NSCLC (China). US BLA (endometrial) under priority review", "NCT06132958 (TroFuse-005)", "Merck & Co./MSD (ex-Greater China)", "2022 (reported 2022-05-19)", "TroFuse-005 Ph3 (endometrial) OS 19.0 vs 12.1 mo published in Lancet/ESMO 2026; FDA BLA accepted, PDUFA 2027-06-15", "2026-10-26", "www.biopharminternational.com gxpnews.net www.chemexpress.com", "2026-10-26"], ["7", "Shutailai (A166)", "trastuzumab botidotin", "Sichuan Kelun-Biotech", "China", "HER2", "Duostatin-5 (tubulin inhibitor; MMAF-class)", "Approved (NMPA)", "Unresectable/metastatic HER2+ breast cancer after >=1 prior therapy", "NCT06968585 (Ph3 vs T-DM1)", "", "", "NMPA marketing approval", "2025-10-17", "www.thepharmaletter.com www.chemexpress.com clinicaltrials.gov", "2025-10-17"], ["13", "DP303c", "trastuzumab envedotin", "CSPC Pharmaceutical Group", "China", "HER2", "MMAE (tubulin inhibitor; DAR ~2)", "Phase 3 complete - NDA under NMPA review", "Unresectable/metastatic HER2+ breast cancer after >=1 anti-HER2 therapy", "NCT06313086 (Ph3 vs T-DM1)", "", "", "NMPA accepted NDA (Ph3 PFS superior to T-DM1)", "2026-07-17", "doc.irasia.com db.antibodysociety.org clinicaltrials.gov", "2026-07-17"], ["10", "DB-1303 / BNT323", "trastuzumab pamirtecan", "Duality Biotherapeutics (DualityBio)", "China", "HER2", "P1003 / pamirtecan (topoisomerase I inhibitor)", "Phase 3 complete - BLA under NMPA review", "2L HER2+ unresectable/metastatic breast cancer", "NCT06265428 (DB-1303-O-3001); NCT06018337 (DYNASTY-Breast02); NCT06340568 (global Ph3 endometrial)", "BioNTech (ex-mainland China, HK, Macau)", "2023-04-03", "NMPA accepted BLA (Ph3 vs T-DM1 met PFS)", "2026-04-09", "www.onclive.com www.biontech.com", "2026-04-09"], ["14", "HS-20093 / GSK5764227", "risvutatug rezetecan", "Hansoh Pharmaceutical", "China", "B7-H3", "Topoisomerase I inhibitor", "Phase 3 complete - BLA under NMPA review", "SCLC progressed after platinum chemotherapy", "NCT06498479 (ARTEMIS-008); NCT06526624; NCT06935409", "GSK (ex-mainland China, HK, Macau, Taiwan)", "2023-12", "NMPA accepted BLA; ARTEMIS-008 OS 18.5 vs 10.3 mo (HR 0.46) at WCLC 2026", "2026-09-02", "www1.hkexnews.hk ascopost.com www.biospace.com db.antibodysociety.org", "2026-09-16"], ["11", "IBI343 / TAK-921", "arcotatug tavatecan", "Innovent Biologics", "China", "CLDN18.2", "Exatecan (topoisomerase I inhibitor)", "Phase 3 complete - NDA under NMPA priority review", "CLDN18.2+ gastric/GEJ adenocarcinoma after >=2 prior lines", "NCT06238843 (G-HOPE-001, China/Japan); NCT07066098 (Ph3 pancreatic)", "Takeda (ex-Greater China)", "2025-10-21", "Ph3 met PFS at interim; NMPA accepted NDA with priority review (world's first CLDN18.2 ADC filing)", "2026-06-04", "www.fiercebiotech.com www.takeda.com www.chemexpress.com", "2026-06-30"], ["15", "YL201", "tambotatug pelitecan", "MediLink Therapeutics", "China", "B7-H3", "Topoisomerase I inhibitor (TMALIN platform, DAR 8)", "Phase 3 complete - NDA accepted by China CDE", "Relapsed SCLC after 1 prior platinum line", "NCT06612151 (TAISHAN-302); NCT06629597 (TAISHAN-301 NPC); NCT07739758; NCT07487896", "Roche (worldwide ex-mainland China, HK, Macau)", "2026-01", "TAISHAN-302 Ph3: OS 13.3 vs 9.4 mo (HR 0.46), WCLC 2026 + NEJM; China NDA accepted; Roche to start global Ph3", "2026-09-13", "www.roche.com ascopost.com", "2026-09-13"], ["12", "LM-302 (TPX-4589)", "tecotabart vedotin", "Sino Biopharmaceutical (LaNova Medicines subsidiary) (wholly owned by Sino Biopharmaceutical)", "China", "CLDN18.2", "MMAE (tubulin inhibitor)", "Phase 3 complete (interim) - NDA under NMPA priority review", "CLDN18.2+ gastric/GEJ adenocarcinoma after >=2 prior lines", "NCT06351020 (Ph3 3L+); NCT07385703 (Ph3 1L combo)", "None currently (Turning Point/BMS license of May 2022 terminated by BMS Oct 2024)", "2022-05 (terminated 2024-10)", "NMPA accepted NDA (priority review); full Ph3 data expected early 2027", "2026-06-23", "www.zhitongcaijing.com www.apexonco.com www.chemexpress.com", "2026-06-23"], ["28", "JSKN003", "", "Alphamab Oncology", "China", "HER2 (biparatopic)", "Topoisomerase I inhibitor", "Phase 3 (4 Ph3 trials)", "HER2-low mBC; PROC; HER2+ mBC vs T-DM1; HER2+ CRC", "NCT06079983; NCT06751485; NCT06846437; NCT07384377", "", "", "4th Ph3 (HER2+ CRC) first patient dosed Feb 2026; FDA BTD in HER2-expressing PROC (Dec 2025)", "2026-03-25", "www1.hkexnews.hk www.pharmafocusasia.com", "2026-03-25"], ["31", "TQB2102", "rolditamig deuderuxtecan (name per press; INN status not confirmed)", "Chia Tai Tianqing (Sino Biopharmaceutical)", "China", "HER2 (biparatopic)", "Topoisomerase I inhibitor", "Phase 3 (5 Ph3 trials)", "HER2-low mBC; HER2+ mBC vs T-DM1; neoadjuvant HER2+ BC", "NCT06561607; NCT07008976; NCT07003074; NCT07043725", "Cipla (India, South Africa + 5 emerging markets only)", "2026-08-31", "Cipla license for emerging markets", "2026-08-31", "www.outsourcedpharma.com db.antibodysociety.org", "2026-08-31"], ["17", "SYS6010", "", "CSPC Pharmaceutical Group (CSPC Megalith)", "China", "EGFR", "Topoisomerase I inhibitor", "Phase 3 (positive topline)", "EGFR-mutant advanced NSCLC after EGFR-TKI", "NCT06927986 (SYNSTAR-01); 8 further Ph3 on CT.gov", "", "", "SYNSTAR-01 Ph3 met PFS vs platinum chemo; OS trend positive", "2026-08-26", "filingreader.com clinicaltrials.gov", "2026-08-26"], ["20", "DS-6000 / MK-5909 (R-DXd)", "raludotatug deruxtecan", "Daiichi Sankyo", "Japan", "CDH6", "DXd (topoisomerase I inhibitor)", "Phase 3 (Ph2/3)", "Platinum-resistant ovarian cancer; 1L/2L maintenance ovarian (new Ph3s)", "NCT06161025 (REJOICE-Ovarian01); NCT07776691; NCT07743164; NCT07791732", "Merck & Co./MSD (Daiichi keeps Japan)", "2023-10", "New Merck/Daiichi Ph3 trials in ovarian maintenance started Sep-Oct 2026 (CT.gov); Ph2 part ORR 50.5% (ESMO 2025)", "2026-10-07", "www.merck.com clinicaltrials.gov", "2026-10-07"], ["18", "DS-7300 / MK-2400 (I-DXd)", "ifinatamab deruxtecan", "Daiichi Sankyo", "Japan", "B7-H3", "DXd (topoisomerase I inhibitor)", "Phase 3", "Relapsed ES-SCLC (IDeate-Lung02); also ESCC, mCRPC", "NCT06203210 (IDeate-Lung02); NCT06644781; NCT06925737", "Merck & Co./MSD (global co-development; Daiichi keeps Japan)", "2023-10", "US accelerated-approval BLA (Ph2 IDeate-Lung01) voluntarily withdrawn; filing now depends on Ph3 IDeate-Lung02", "2026-09-25", "www.merck.com", "2026-09-25"], ["19", "U3-1402 / MK-1022 (HER3-DXd)", "patritumab deruxtecan", "Daiichi Sankyo", "Japan", "HER3", "DXd (topoisomerase I inhibitor)", "Phase 3", "HR+/HER2- metastatic breast cancer (HERTHENA-Breast04); EGFRm NSCLC (HERTHENA-Lung02, OS not significant)", "NCT07060807 (HERTHENA-Breast04); NCT05338970 (HERTHENA-Lung02)", "Merck & Co./MSD (Daiichi keeps Japan)", "2023-10", "HERTHENA-Breast04 Ph3 enrolling (started 2025-07-21); US NSCLC BLA withdrawn 2025-05", "2026-06-04", "www.onclive.com www.indianpharmapost.com", "2026-06-04"], ["21", "DB-1311 / BNT324", "", "Duality Biotherapeutics (DualityBio)", "China", "B7-H3", "Topoisomerase I inhibitor (DAR 6)", "Phase 3 (global)", "Metastatic castration-resistant prostate cancer vs docetaxel", "NCT07365995", "BioNTech (ex-mainland China, HK, Macau; Duality US co-development option)", "2023-04-03", "Global Ph3 in mCRPC started (CT.gov start 2026-04-22)", "2026-04-22", "www.fiercebiotech.com clinicaltrials.gov www.biontech.com", "2026-04-22"], ["30", "HS-20089 / GSK5733584", "", "Hansoh Pharmaceutical", "China", "B7-H4", "Topoisomerase inhibitor", "Phase 3", "Platinum-resistant recurrent epithelial ovarian cancer; new Ph3 in platinum-sensitive OC", "NCT06855069; NCT07821606", "GSK (ex-mainland China, HK, Macau, Taiwan)", "2023-10-20", "New Ph3 (with bevacizumab, PSOC) registered, start 2026-11-01", "2026-11-01", "www.gsk.com clinicaltrials.gov", "2026-11-01"], ["35", "IBI354", "", "Innovent Biologics", "China", "HER2", "Not disclosed in sources opened (hydrophobic payload, DAR 8)", "Phase 3", "Platinum-resistant ovarian cancer (HeriCare-Ovarian01); 1L HER2+ mBC (HeriCare-Breast01)", "NCT06834672; NCT07377643", "", "", "ESMO 2026 Ph2 data (1L HER2+ BC + pertuzumab, ORR 95%)", "2026-10-25", "www.prnewswire.com clinicaltrials.gov", "2026-10-25"], ["32", "SHR-A1904", "", "Jiangsu Hengrui Pharmaceuticals", "China", "CLDN18.2", "Topoisomerase I inhibitor", "Phase 3", "2L CLDN18.2+ advanced gastric/GEJ cancer", "NCT06649292", "Merck KGaA (option for ex-China license; current status not verified)", "2023-10-30", "Ph3 recruiting (CT.gov); NMPA combo IND approvals 2025-06-20", "2025-06-20", "www.biospace.com static.cninfo.com.cn clinicaltrials.gov", "2025-06-21"], ["37", "SHR-A1912", "", "Jiangsu Hengrui Pharmaceuticals", "China", "CD79b", "SHR9265 (topoisomerase I inhibitor)", "Phase 3", "R/R DLBCL (+ R-GemOx)", "NCT06929624", "", "", "Ph3 active, not recruiting (CT.gov update 2026-09-25)", "2026-09-25", "adcdb.idrblab.cn clinicaltrials.gov", "2026-09-25"], ["29", "SHR-A1921", "tizetatug rezetecan", "Jiangsu Hengrui Pharmaceuticals", "China", "TROP2", "SHR9265 / rezetecan (topoisomerase I inhibitor)", "Phase 3; NCT06394492 RECRUITING (status as of 2024-08-09) Registry", "Platinum-resistant recurrent epithelial ovarian cancer", "NCT06394492; NCT06211023", "", "", "Ph3 in PROC recruiting (CT.gov)", "2024-05-10", "db.antibodysociety.org clinicaltrials.gov", "2024-05-10"], ["33", "SHR-A2009", "", "Jiangsu Hengrui Pharmaceuticals", "China", "HER3", "Topoisomerase I inhibitor", "Phase 3", "EGFR-mutant advanced NSCLC (post-TKI; and 1L + aumolertinib)", "NCT06671379; NCT07183189; NCT07895992", "", "", "New Ph3 (with bevacizumab, nsqNSCLC) registered, start 2026-11-30", "2026-11-30 (planned)", "db.antibodysociety.org clinicaltrials.gov", "2026-10"], ["34", "SHR-A2102", "", "Jiangsu Hengrui Pharmaceuticals", "China", "Nectin-4", "SHR169265 (topoisomerase I inhibitor)", "Phase 3", "Advanced urothelial carcinoma; MIBC; platinum-pretreated (NCT07418749)", "NCT06738251; NCT07393542; NCT06879145; NCT07418749", "", "", "Ph1 published in Lancet Oncology", "2026-09-09", "stock.10jqka.com.cn db.antibodysociety.org clinicaltrials.gov", "2026-09-09"], ["16", "CMG901 / AZD0901", "sonesitatug vedotin", "KYM Biosciences (JV: Keymed Biosciences 70% / Lepu Biopharma 30%)", "China", "CLDN18.2", "MMAE (per INN suffix -vedotin)", "Phase 3 (positive topline)", "2L+ CLDN18.2+ gastric/GEJ/esophageal adenocarcinoma", "NCT06346392 (CLARITY-Gastric01); NCT07431281", "AstraZeneca (global incl. China)", "2023-02-23", "CLARITY-Gastric01 global Ph3 positive: OS benefit (dual primary OS in 3L+ met; PFS not significant)", "2026-07-28", "www1.hkexnews.hk www.pharmafocusasia.com clinicaltrials.gov", "2026-07-28"], ["26", "MRG002", "", "Lepu Biopharma / Shanghai Miracogen", "China", "HER2", "MMAE (tubulin inhibitor)", "Phase 3; NCT05754853 RECRUITING (status as of 2023-04-13) Registry", "HER2+ la/m urothelial cancer (also HER2+ BC Ph3, status unknown)", "NCT05754853; NCT04924699", "", "", "Ph3 in HER2+ UC registered as recruiting (no newer verified event found)", "2023-04-13", "db.antibodysociety.org clinicaltrials.gov", "2023-04-13"], ["25", "LCB14 / FS-1502 / IKS014", "caxmotabart entudotin", "LigaChem Biosciences (formerly LegoChem Biosciences)", "South Korea", "HER2", "MMAF (tubulin inhibitor; site-specific, DAR 2)", "Phase 3 (China, by Fosun); NCT05755048 UNKNOWN (status as of 2023-09-01) Registry", "HER2+ mBC vs T-DM1", "NCT05755048 (Fosun Ph3); NCT05872295 (Iksuda Ph1)", "Iksuda Therapeutics (worldwide ex-Greater China & Korea); Fosun Pharma holds Greater China", "2022-01-10 (Iksuda)", "Ligachem R&D Day: Fosun Ph3 ongoing in China; IKS014 global Ph1 RP2D 105 mg/m2, ORR 35-40%", "2026-07-08", "biz.newdaily.co.kr db.antibodysociety.org www.businesswire.com", "2026-07-08"], ["27", "9MW2821", "bulumtatug fuvedotin", "Mabwell (Shanghai) Bioscience", "China", "Nectin-4", "MMAE (tubulin inhibitor)", "Phase 3 (4 Ph3 trials)", "2L+ urothelial carcinoma (enrollment complete); cervical; 1L UC + toripalimab; TNBC", "NCT06196736; NCT06592326; NCT06692166; NCT07556848", "", "", "4 Ph3 ongoing; UC/CC interim analyses planned 2H26, then pre-NDA with NMPA", "2026-08-30", "www1.hkexnews.hk db.antibodysociety.org www.biospace.com", "2026-08-30"], ["39", "YL202 / BNT326", "", "MediLink Therapeutics", "China", "HER3", "Not verified", "Phase 3", "HR+/HER2- breast cancer; EGFR-sensitizing NSCLC vs docetaxel", "NCT07461454; NCT07416994", "BioNTech (ex-China, HK, Macau) - current status not re-verified", "2023 (~Oct, per FierceBiotech)", "Two pivotal Ph3 trials started in China (Mar 2026)", "2026-03-18", "www.fiercebiotech.com clinicaltrials.gov", "2026-03-18"], ["38", "MHB088C", "", "Minghui Pharmaceutical", "China", "B7-H3", "Not verified", "Phase 3", "Relapsed SCLC vs physician's choice", "NCT06954246 (Qilu-sponsored)", "Minghui retains ex-Greater China rights (Qilu licensed Greater China)", "2025-05 (Qilu, Greater China)", "Ph3 recruiting (started 2025-06-04)", "2025-06-04", "www.fiercebiotech.com www.apexonco.com clinicaltrials.gov", "2025-06-18"], ["36", "FDA018", "", "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical", "China", "TROP2", "SN-38 (topoisomerase I inhibitor)", "Phase 3", "Taxane-pretreated la/m TNBC", "NCT06519370", "", "", "Ph3 active, not recruiting (CT.gov update 2026-01-22)", "2026-01-22", "db.antibodysociety.org clinicaltrials.gov", "2026-01-22"], ["23", "HLX43", "", "Shanghai Henlius Biotech", "China", "PD-L1", "Topoisomerase I inhibitor (linker in-licensed)", "Phase 3 (global Ph2/3)", "Previously treated advanced/metastatic squamous NSCLC vs docetaxel", "NCT07459751", "", "", "First patient dosed in global Ph2/3 (HLX43 +/- HLX07)", "2026-05-28", "www.hkexnews.hk clinicaltrials.gov", "2026-05-28"], ["40", "JS107", "", "Shanghai Junshi Biosciences (TopAlliance)", "China", "CLDN18.2", "MMAE (tubulin inhibitor)", "Phase 3", "2L+ CLDN18.2+ gastric/GEJ adenocarcinoma; 1L combo", "NCT07284134; NCT07584135", "", "", "Ph3 started (2025-12-24); 1L combo Ph3 started 2026-05-28", "2026-05-28", "adcdb.idrblab.cn clinicaltrials.gov", "2026-05"], ["24", "BL-M07D1 (T-Bren)", "", "Sichuan Baili Pharmaceutical (Biokin) / SystImmune", "China", "HER2", "Ed-04 (topoisomerase I inhibitor)", "Phase 3 (9 Ph3 trials)", "HER2+ mBC vs T-DM1 (most advanced); also HER2-low BC, NSCLC, BTC, CRC, PROC", "NCT06316531; NCT06957886; NCT06830889; NCT06891833; NCT07178795; NCT07545460", "", "", "9th Ph3 started (HER2-expressing PROC); CDE BTDs in HER2+ GC and BTC", "2026-09-30", "pdf.dfcfw.com oncodaily.com clinicaltrials.gov", "2026-09-30"], ["22", "ZL-1310", "zocilurtatug pelitecan", "Zai Lab (built on TMALIN platform)", "China", "DLL3", "Camptothecin derivative (topoisomerase I inhibitor)", "Phase 3 (global)", "2L+ ES-SCLC (DLLEVATE)", "NCT07218146 (DLLEVATE); NCT07796100 (1L Ph3, not yet recruiting)", "Zai Lab retains global rights (Amgen = combination-trial collaborator only)", "", "DLLEVATE on track, enrollment complete expected 1H27; potential US accelerated filing 2027", "2026-08-06", "www.biospace.com www.businesswire.com clinicaltrials.gov", "2026-08-06"]], "row_sources": [[{"url": "https://newsroom.astellas.com/2026-07-13-us-fda-approves-padcev-plus-keytruda-as-neoadjuvant-and-adjuvant-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility", "label": "newsroom.astellas.com"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://www.lse.co.uk/rns/datroway-approved-in-us-for-1l-triple-negative-bc-qm1wd5f8h7hdfdz.html", "label": "www.lse.co.uk"}, {"url": "https://clinicaltrials.gov/study/NCT05374512", "label": "clinicaltrials.gov"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://news.10jqka.com.cn/20261009/c680513217.shtml", "label": "news.10jqka.com.cn"}, {"url": "https://www.astrazeneca.com/media-centre/press-releases/2026/enhertu-approved-in-two-her2-early-bc-settings.html", "label": "www.astrazeneca.com"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://static.cninfo.com.cn/finalpage/2026-08-07/1225462406.PDF", "label": "static.cninfo.com.cn"}, {"url": "https://news.10jqka.com.cn/20260708/c678035437.shtml", "label": "news.10jqka.com.cn"}, {"url": "https://www.theweek.in/wire-updates/business/2025/09/24/dcm96-biz-glenmark-hengrui-pharma.html", "label": "www.theweek.in"}], [{"url": "https://global.pharmcube.com/news/detail/3c233921b632432b9df57d3777ed6111", "label": "global.pharmcube.com"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://news.qq.com/rain/a/20260522A075UG00", "label": "news.qq.com"}, {"url": "https://www.cancernetwork.com/view/disitamab-vedotin-toripalimab-combo-prolongs-survival-in-frontline-her2-uc", "label": "www.cancernetwork.com"}, {"url": "https://www.businesswire.com/news/home/20210809005208/en", "label": "www.businesswire.com"}], [{"url": "https://www.biochempeg.com/article/1479.html", "label": "www.biochempeg.com"}, {"url": "https://www.biopharminternational.com/view/china-nmpa-approves-iza-bren-for-nasopharyngeal-carcinoma-marking-first-global-bispecific-adc-approval", "label": "www.biopharminternational.com"}, {"url": "https://www.biopharminternational.com/view/bristol-myers-squibb-and-systimmune-enter-global-adc-collaboration-worth-potentially-up-to-8-4-billion", "label": "www.biopharminternational.com"}], [{"url": "https://www.biopharminternational.com/view/merck-and-kelun-s-sac-tmt-extends-survival-by-nearly-7-months-in-pretreated-endometrial-cancer", "label": "www.biopharminternational.com"}, {"url": "https://gxpnews.net/2022/05/merck-pokupaet-lekarstvo-ot-raka-u-kitajskoj-kompanii-kelun-za-14-mlrd/?amp=1", "label": "gxpnews.net"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://www.thepharmaletter.com/biotech-news/kelun-secures-china-approval-for-first-homegrown-her2-breast-cancer-adc", "label": "www.thepharmaletter.com"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}, {"url": "https://clinicaltrials.gov/study/NCT06968585", "label": "clinicaltrials.gov"}], [{"url": "https://doc.irasia.com/listco/hk/cspc/announcement/a260717.pdf", "label": "doc.irasia.com"}, {"url": "https://db.antibodysociety.org/db0/567", "label": "db.antibodysociety.org"}, {"url": "https://clinicaltrials.gov/study/NCT06313086", "label": "clinicaltrials.gov"}], [{"url": "https://www.onclive.com/view/bla-is-accepted-in-china-for-trastuzumab-pamirtecan-in-her2-metastatic-breast-cancer", "label": "www.onclive.com"}, {"url": "https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html", "label": "www.biontech.com"}], [{"url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0902/2026090200764.pdf", "label": "www1.hkexnews.hk"}, {"url": "https://ascopost.com/news/september-2026/two-phase-iii-trials-explore-b7-h3-directed-adcs-in-relapsed-sclc/", "label": "ascopost.com"}, {"url": "https://www.biospace.com/drug-development/gsk-and-hansohs-adc-clinches-late-stage-win-teeing-up-regulatory-submission-in-china", "label": "www.biospace.com"}, {"url": "https://db.antibodysociety.org/db0/734", "label": "db.antibodysociety.org"}], [{"url": "https://www.fiercebiotech.com/biotech/innovent-fresh-12b-deal-posts-phase-3-win-cldn182-adc", "label": "www.fiercebiotech.com"}, {"url": "https://www.takeda.com/newsroom/newsreleases/2025/innovent/", "label": "www.takeda.com"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://www.roche.com/media/releases/med-cor-2026-09-13", "label": "www.roche.com"}, {"url": "https://ascopost.com/news/september-2026/two-phase-iii-trials-explore-b7-h3-directed-adcs-in-relapsed-sclc/", "label": "ascopost.com"}], [{"url": "https://www.zhitongcaijing.com/content/detail/1457474.html", "label": "www.zhitongcaijing.com"}, {"url": "https://www.apexonco.com/node/909", "label": "www.apexonco.com"}, {"url": "https://www.chemexpress.com/news-and-events/news/adc-global-landscape-2026H1", "label": "www.chemexpress.com"}], [{"url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0325/2026032502261.pdf", "label": "www1.hkexnews.hk"}, {"url": "https://www.pharmafocusasia.com/index.php/news/alphamab-oncologys-anti-her2-biparatopic-adc-jskn003-receives-approval", "label": "www.pharmafocusasia.com"}], [{"url": "https://www.outsourcedpharma.com/doc/cipla-and-sbp-group-potential-best-in-class-her-bispecific-adc-rolditamig-deuderuxtecan-tqb-0001", "label": "www.outsourcedpharma.com"}, {"url": "https://db.antibodysociety.org/db0/1374", "label": "db.antibodysociety.org"}], [{"url": "https://filingreader.com/news-wire/hongkong/2026-08-26/cspc-reports-positive-phase-iii-results-for-sys6010", "label": "filingreader.com"}, {"url": "https://clinicaltrials.gov/study/NCT06927986", "label": "clinicaltrials.gov"}], [{"url": "https://www.merck.com/news/raludotatug-deruxtecan-demonstrated-clinically-meaningful-response-rates-in-patients-with-recurrent-platinum-resistant-ovarian-primary-peritoneal-or-fallopian-tube-cancer-in-phase-2-part-of-rejoice-o/", "label": "www.merck.com"}, {"url": "https://clinicaltrials.gov/study/NCT07743164", "label": "clinicaltrials.gov"}], [{"url": "https://www.merck.com/news/ifinatamab-deruxtecan-biologics-license-application-for-certain-patients-with-previously-treated-extensive-stage-small-cell-lung-cancer-voluntarily-withdrawn/", "label": "www.merck.com"}], [{"url": "https://www.onclive.com/view/herthena-breast04-is-set-to-delineate-the-role-of-her3-targeted-therapy-in-advanced-hr-breast-cancer", "label": "www.onclive.com"}, {"url": "https://www.indianpharmapost.com/regulatory/merck-withdraws-biologics-license-application-for-patritumab-deruxtecan-17223", "label": "www.indianpharmapost.com"}], [{"url": "https://www.fiercebiotech.com/biotech/biontech-advances-dualitybio-adc-phase-3-half-patients-merck-daiichi-rival", "label": "www.fiercebiotech.com"}, {"url": "https://clinicaltrials.gov/study/NCT07365995", "label": "clinicaltrials.gov"}, {"url": "https://www.biontech.com/us/en/home/mediaroom/news/press-releases/2023/04/biontech-and-dualitybio-form-global-strategic-partnership.html", "label": "www.biontech.com"}], [{"url": "https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089/", "label": "www.gsk.com"}, {"url": "https://clinicaltrials.gov/study/NCT07821606", "label": "clinicaltrials.gov"}], [{"url": "http://www.prnewswire.com/news-releases/2026-esmo--innovent-announcement-phase-2-data-presentation-for-ibi354-her2-adc-in-first-line-treatment-of-breast-cancer-302918639.html", "label": "www.prnewswire.com"}, {"url": "https://clinicaltrials.gov/study/NCT06834672", "label": "clinicaltrials.gov"}], [{"url": "https://www.biospace.com/merck-kgaa-darmstadt-germany-strengthens-oncology-pipeline-through-strategic-partnership-with-hengrui-for-next-generation-selective-parp1-inhibitor-and-antibody-drug-conjugate", "label": "www.biospace.com"}, {"url": "https://static.cninfo.com.cn/finalpage/2025-06-21/1223951591.PDF", "label": "static.cninfo.com.cn"}, {"url": "https://clinicaltrials.gov/study/NCT06649292", "label": "clinicaltrials.gov"}], [{"url": "https://adcdb.idrblab.cn/data/adc/details/DRG0YXBEH", "label": "adcdb.idrblab.cn"}, {"url": "https://clinicaltrials.gov/study/NCT06929624", "label": "clinicaltrials.gov"}], [{"url": "https://clinicaltrials.gov/api/v2/studies/NCT06394492", "label": "Registry"}, {"url": "https://db.antibodysociety.org/db0/1282", "label": "db.antibodysociety.org"}, {"url": "https://clinicaltrials.gov/study/NCT06394492", "label": "clinicaltrials.gov"}], [{"url": "https://db.antibodysociety.org/db0/1283", "label": "db.antibodysociety.org"}, {"url": "https://clinicaltrials.gov/study/NCT06671379", "label": "clinicaltrials.gov"}], [{"url": "https://stock.10jqka.com.cn/20260909/c679747764.shtml", "label": "stock.10jqka.com.cn"}, {"url": "https://db.antibodysociety.org/db0/1284", "label": "db.antibodysociety.org"}, {"url": "https://clinicaltrials.gov/study/NCT06738251", "label": "clinicaltrials.gov"}], [{"url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0728/2026072800183.pdf", "label": "www1.hkexnews.hk"}, {"url": "https://www.pharmafocusasia.com/index.php/news/astrazeneca-enters-licence-agreement-with-kym-biosciences", "label": "www.pharmafocusasia.com"}, {"url": "https://clinicaltrials.gov/study/NCT06346392", "label": "clinicaltrials.gov"}], [{"url": "https://clinicaltrials.gov/api/v2/studies/NCT05754853", "label": "Registry"}, {"url": "https://db.antibodysociety.org/db0/1028", "label": "db.antibodysociety.org"}, {"url": "https://clinicaltrials.gov/study/NCT05754853", "label": "clinicaltrials.gov"}], [{"url": "https://clinicaltrials.gov/api/v2/studies/NCT05755048", "label": "Registry"}, {"url": "https://biz.newdaily.co.kr/site/data/html/2026/07/08/2026070800110.html", "label": "biz.newdaily.co.kr"}, {"url": "https://db.antibodysociety.org/db0/787", "label": "db.antibodysociety.org"}, {"url": "https://www.businesswire.com/news/home/20220110005078/en", "label": "www.businesswire.com"}], [{"url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0830/2026083000033.pdf", "label": "www1.hkexnews.hk"}, {"url": "https://db.antibodysociety.org/db0/178/", "label": "db.antibodysociety.org"}, {"url": "https://www.biospace.com/press-releases/esmo-2026-mabwell-to-present-latest-clinical-data-on-nectin-4-targeting-adc-9mw2821-for-triple-negative-breast-cancer-in-oral-presentation", "label": "www.biospace.com"}], [{"url": "https://www.fiercebiotech.com/biotech/biontech-takes-another-leaf-out-daiichi-playbook-paying-70m-her3-directed-adc", "label": "www.fiercebiotech.com"}, {"url": "https://clinicaltrials.gov/study/NCT07416994", "label": "clinicaltrials.gov"}], [{"url": "https://www.fiercebiotech.com/biotech/qilu-pharmaceutical-pays-38m-upfront-greater-china-rights-minghuis-adc-cancer-drug", "label": "www.fiercebiotech.com"}, {"url": "https://www.apexonco.com/node/1312?page=11", "label": "www.apexonco.com"}, {"url": "https://clinicaltrials.gov/study/NCT06954246", "label": "clinicaltrials.gov"}], [{"url": "https://db.antibodysociety.org/db0/625/", "label": "db.antibodysociety.org"}, {"url": "https://clinicaltrials.gov/study/NCT06519370", "label": "clinicaltrials.gov"}], [{"url": "https://www.hkexnews.hk/listedco/listconews/sehk/2026/0528/2026052800515.pdf", "label": "www.hkexnews.hk"}, {"url": "https://clinicaltrials.gov/study/NCT07459751", "label": "clinicaltrials.gov"}], [{"url": "https://adcdb.idrblab.cn/data/adc/details/DRG0LSXKR", "label": "adcdb.idrblab.cn"}, {"url": "https://clinicaltrials.gov/study/NCT07284134", "label": "clinicaltrials.gov"}], [{"url": "https://pdf.dfcfw.com/pdf/H2_AN202609291830002074_1.pdf", "label": "pdf.dfcfw.com"}, {"url": "https://oncodaily.com/breast-oncology/t-bren", "label": "oncodaily.com"}, {"url": "https://clinicaltrials.gov/study/NCT06316531", "label": "clinicaltrials.gov"}], [{"url": "https://www.biospace.com/press-releases/zai-lab-announces-second-quarter-2026-financial-results-and-recent-corporate-updates", "label": "www.biospace.com"}, {"url": "https://www.businesswire.com/news/home/20241024949177/en", "label": "www.businesswire.com"}, {"url": "https://clinicaltrials.gov/study/NCT07218146", "label": "clinicaltrials.gov"}]]}